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EUCAST acknowledges the difficulties encountered (Meylan and Guerin \[[@bib1]\]) when attempting to disseminate new information concerning antimicrobial susceptibility testing (AST). This is especially true for colleagues outside our specialties. We also agree that unless colleagues have understood and accepted the rationale behind the new S (susceptible, standard dose), I (susceptible, increased exposure) and R (resistant) definitions, this may lead to an increased use of meropenem for the treatment of *Pseudomonas* infections since most other agents will be categorised as "susceptible, increased exposure". EUCAST had planned to use 2020 as the year during which all changes would be thoroughly explained and gradually implemented. COVID-19 put a spanner in everyone´s wheel. It became very difficult to elicit much interest in anything but the pandemic.

The change was necessary. The old definition of "intermediate" (I), crafted by EUCAST 2002 -- 2018 \[[@bib2]\] and embedded in the original 2006 version of ISO standard 20776-1 \[[@bib3]\], had proven difficult to understand and nigh on useless in everyday practice. This was primarily due to its multiple meanings (underlined): "A microorganism is defined as intermediate by a level of antimicrobial agent activity associated with [uncertain therapeutic effect.]{.ul} It implies that an infection due to the isolate [may be appropriately treated in body sites where the drugs are physiologically concentrated]{.ul} or when [a high dosage of drug can be used]{.ul}; it also indicates [a buffer zone that should prevent small, uncontrolled, technical factors]{.ul} from causing major discrepancies in interpretations".

Most colleagues ignored an "I" and looked for an "S" and we learnt of colleagues who converted every "I" to "R" in the report. Surveillance systems lumped "I" and "R" under "non-susceptible". To make things worse, many colleagues liked wide "intermediate" categories because these prevented or reduced very major (VME) and major errors (ME) in AST -- the wider the "intermediate" category, the fewer VMEs and MEs. While this may seem attractive, the lack of clarity of the definition and an abundance of intermediate results, would continue to drive the use of broader and more expensive antimicrobials. The assumption by Meylan and Guery \[[@bib1]\] is most certainly correct -- the gut reaction of most colleagues is to go looking for that "S" because they do not trust "I" to be useful. Which proves our point.

EUCAST is now resurrecting the usefulness of this susceptibility category. A discussion of changing definitions, and possibly the letters S, I and R, was started in 2014. During three public consultations 2015 -- 2018, the arguments and proposals brought forward by Meylan and Guery, and many more, were discussed and commented on by EUCAST (see <https://www.eucast.org/documents/consultations/> for three public consultations directly related to the change and two related to the consequences in reporting and dosing). All comments were discussed and responded to by EUCAST as is evident when reading these. In preparation for all major decisions, EUCAST encourages National AST Committees (NACs) to to discuss and inform national colleagues and to respond to consultations - all NACs were addressed, including the Swiss NAC -- their response will be among the others.

The "Susceptible Dose Dependent (SDD)" category first appears in an article 1997 by Rex et al and relates to fluconazole in antifungal AST \[[@bib4]\]. It is later introduced by CLSI, primarily with antifungal susceptibility testing, but later also for a few antibacterial agents (cefepime (CLSI M100-S14 (2014)) and subsequently ceftaroline and daptomycin). EUCAST evaluated but decided against adopting SDD. The discussion between CLSI and EUCAST representatives was recently published as a point-counterpoint \[[@bib5]\]. EUCAST took the view that all breakpoints are really dose-dependent, and that a three-letter category and a fourth category should be avoided (the CLSI system has S, I, SDD and R). Systems with difficulties changing one letter would have even more difficulties with a three-letter category and a fourth category. Neither antibacterial (as opposed to antifungal) susceptibility testing devices nor most Laboratory Information Systems (LIS) handle SDD or a fourth category. Through the EUCAST public consultations and distributed questionnaires we knew that \>80% of colleagues were in favour of not changing the letter "I". These included the European Medicines Agency (EMA), the European Centre for Disease Prevention and Control (ECDC) and the European Society for Clinical Microbiology and Infectious Diseases (ESCMID), as well as the manufacturers of AST devices, all of which predicted lengthy and drawn-out procedures if a change of letter was to be managed. The delay in implementation and the confusion created by a change which would be impossible to synchronise needed to be avoided. To address the element of technical uncertainty built into the previous definition of "I", the committee decided to carefully analyse where the major problems lay. Laboratories are since the change warned by the introduction in tables of the "Area of Technical Uncertainty (ATU)", often caused by a combination of natural variation in tests and poor separation between isolates without and with resistance mechanisms to the agent (eg. Piperacillin-tazobactam and Enterobacterales).

Implementation of EUCAST guidance is a shared responsibility. EUCAST, ESCMID, European agencies, NACs, national societies, and local stewardship teams and laboratories - all have important roles in making sure colleagues have understood the meaning of the new "Susceptible, increased exposure" and in adopting systems to cope. With the support of EUCAST, NACs have the most important role. We advise all concerned colleagues to contact their NACs to offer their help and assistance, as well as to obtain updates on what has already been done and what is planned on a national level. NACs are encouraged to use the various material made available by EUCAST for national translation and distribution to colleagues.
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